Rohan Sharma, MD
Hematology & Oncology · Scottsdale, AZNPI 1053686394
Payments from drug & device makers
Across 80 payments — averaging $158.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Jazz Pharmaceuticals Inc.$2K
- Beigene USA, Inc.$2K
- Taiho Oncology, Inc.$1K
- Daiichi Sankyo Inc.$992
- Novocure GmbH$250
- plus $2K from 32 others
What the payments were for
- Consulting fees$10,12580%
- Speaking & faculty fees$2502%
- Travel & lodging$2352%
- Food & beverage$2,01716%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $4,491 |
| Jazz Pharmaceuticals Inc. | 4 | $2,207 |
| Beigene USA, Inc. | 2 | $1,938 |
| Taiho Oncology, Inc. | 1 | $1,088 |
| Daiichi Sankyo Inc. | 2 | $992 |
| Novocure GmbH | 1 | $250 |
| E.r. Squibb & Sons, L.L.C. | 8 | $224 |
| Icotec Medical Inc. | 2 | $170 |
| Progenics Pharmaceuticals, Inc. | 1 | $122 |
| Seagen Inc. | 1 | $120 |
| Rigel Pharmaceuticals, Inc. | 2 | $86 |
| Sanofi | 4 | $85 |
| Lilly USA, LLC | 4 | $77 |
| Novartis | 3 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $63 |
| Pfizer | 3 | $62 |
| Johnson & Johnson | 3 | $59 |
| Davol Inc. | 1 | $50 |
| Intuitive Surgical | 1 | $49 |
| Bayer | 2 | $48 |
| Bristol Myers Squibb | 2 | $44 |
| Amgen | 2 | $41 |
| Genentech USA, Inc. | 2 | $35 |
| Incyte Corporation | 2 | $33 |
| Boehringer Ingelheim | 1 | $32 |
| Verastem, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Mylan Institutional Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,660 in reported general payments places this provider in the 40th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 31 | $375,199 |
| ErleadaApalutamide | 22 | $335,853 |
| RevlimidLenalidomide | 16 | $326,367 |
| CalquenceAcalabrutinib Maleate | 18 | $277,727 |
| Lenalidomide | 14 | $201,628 |
| BrukinsaZanubrutinib | 14 | $145,253 |
| EliquisApixaban | 197 | $135,135 |
| XospataGilteritinib Fumarate | 12 | $107,135 |
| XareltoRivaroxaban | 96 | $82,459 |
| VenclextaVenetoclax | 26 | $46,084 |
| Abiraterone Acetate | 43 | $31,308 |
| Imatinib Mesylate | 18 | $11,436 |
| ValacyclovirValacyclovir Hcl | 18 | $945 |
| Letrozole | 21 | $928 |
| Dexamethasone | 32 | $842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $59 | $418,312118 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $63 | $375,19931 claims |
| Bristol Myers SquibbRevlimid | $44 | $326,36716 claims |
| AstraZenecaCalquence | $4,491 | $277,72718 claims |
| Beigene USA, Inc.Brukinsa | $1,938 | $145,25314 claims |
| PfizerEliquis | $62 | $135,135197 claims |
| Astellas Pharma US IncXospata | $11 | $107,13512 claims |
| AbbVieVenclexta | $15 | $46,08426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.